Comparative Pharmacology
Head-to-head clinical analysis: FLUORINE F 18 versus STRONTIUM CHLORIDE SR 89.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORINE F 18 versus STRONTIUM CHLORIDE SR 89.
FLUORINE F-18 vs STRONTIUM CHLORIDE SR-89
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorine-18 decays by positron emission, and the emitted positron annihilates with an electron to produce two 511 keV gamma photons. When incorporated into radiopharmaceuticals such as fludeoxyglucose F-18, it accumulates in metabolically active tissues, enabling PET imaging.
Strontium-89 is a calcium mimetic that localizes to bone, particularly areas of increased osteoblastic activity, emitting beta radiation that causes DNA damage and cell death in metastatic tumor cells.
2-10 mCi (74-370 MBq) intravenous bolus, single administration for PET imaging.
148 MBq (4 mCi) intravenously over 1-2 minutes, single dose. Repeat after 3-6 months if needed.
None Documented
None Documented
Physiological half-life is 109.7 minutes (1.83 hours) for fluorine-18 decay by positron emission, with a physical half-life of 109.7 minutes. The biological half-life is dependent on the radiolabeled compound; for [18F]FDG, the effective half-life is approximately 3-4 hours.
Terminal elimination half-life: 50.5 days (range 33–65 days). Reflects slow clearance from bone; clinical effect persists due to long skeletal retention.
Primarily renal; approximately 95% of administered activity is excreted in urine within 6 hours post-injection. Less than 5% is excreted in feces.
Primarily renal (urinary) excretion; approximately 50-80% of absorbed dose eliminated via urine over 7 days. Fecal elimination is negligible (<5%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical